Sector News

China’s biotech cash injection suddenly drops as U.S. scrutiny intensifies: report

July 9, 2019
Life sciences

China is a big area of opportunity for biotech: It has a population of about 1.4 billion, with a sizable and growing chunk of that demographic succumbing to chronic, middle-class diseases like diabetes, cancer and heart disease.

Regulation is complex, to say the least, but U.S. and European biotech companies know China is an increasingly important area not just to sell medicines, but to discover and develop them as well.

China, too, has been making a big push in the direction of innovation, and is looking to spend considerable sums on Western biopharmas to do so: In the first six months of last year, Chinese investors took part in venture capital funding rounds for U.S. biotech companies worth $1.65 billion.

Much of this cash has been used to fill in the “valley of death”: a gap between getting a promising idea into something more tangible, with cash pots of $20 million and $30 million injected into seed rounds for very young startups hoping to start the journey into the clinic.

Many saw this as the beginning of a trend, with Chinese companies and VCs increasingly looking to help bolster U.S. biotechs. But fast-forward one year, and funding is down by more than half to just $725 million, according to new figures out by Seattle-based data provider PitchBook.

This comes amid increasing trade wars between the U.S. and China, with the White House doubling down on its tough stance against alleged intellectual property theft from the country as well as higher scrutiny over how and where overseas cash injections are coming into the U.S.

In a report from the Financial Times, it appears biotechs and VC investing have been particularly hit. William Haseltine, an American biotech entrepreneur, told the London-based newspaper that he “had been forced to abandon the creation of a new company, Constructive Biology, after a Chinese investor who pledged $30 million in seed money for a fabrication laboratory pulled out.”

He said: “As soon as the Cfius programme went into place (the Committee on Foreign Investment in the U.S. which has started to more deeply review foreign investments}, and [U.S. President Donald] Trump started making a lot of noise about Cfius, [the money] began to evaporate.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.